News
Hinge Health prices IPO at $32/share, valuing company at $3B. CEO Daniel Perez's firm to trade as HNGE on NYSE, raising ...
The FDA's Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen’s mitomycin as an option for low-grade ...
FDA requests Moderna, Pfizer/BioNTech add safety warnings about myocarditis risk to COVID-19 vaccines, with specific rates ...
The FDA said it is making 'enhancements' designed to help states develop programs for importing cheaper drugs from Canada.
Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...
FTC sends new warning letters to Teva, Novartis, Amphastar, Viatris's Mylan, and Covis Pharma over allegedly improper drug ...
BioNTech to invest £1B in UK R&D over 10 years, receives £129M government grant to build research centers and HQ in London, ...
Weill Cornell Medicine study shows cocaine vaccine triggers antibodies & reduces drug use in small trial, but effects modest.
Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...
Moderna pulls BLA for its Covid-flu shot: The company suggested on its most recent … Get free access to a limited ...
Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.
The FDA’s Oncologic Drugs Advisory Committee voted 8-0 against a new indication for Pfizer’s Talzenna in combination with Xtandi for first-line treatment of adults with … Get free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results